Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Unusually-High Trading Volume on Analyst Upgrade

Posted by Geri Gentry on May 11th, 2026

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) saw unusually-strong trading volume on Monday after Citigroup raised their price target on the stock from $2.30 to $3.10. Citigroup currently has a buy rating on the stock. Approximately 2,324,336 shares changed hands during trading, a decline of 13% from the previous session’s volume of 2,662,020 shares.The stock last traded at $2.3450 and had previously closed at $2.00.

A number of other analysts have also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Lexicon Pharmaceuticals in a research note on Monday, March 23rd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.55.

Check Out Our Latest Analysis on LXRX

Insider Activity at Lexicon Pharmaceuticals

In related news, Director Raymond Debbane purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the purchase, the director directly owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. This represents a 5.54% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders purchased 252,000 shares of company stock valued at $369,980. Insiders own 14.00% of the company’s stock.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $39,000. Security National Bank of Sioux City Iowa IA bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at about $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals in the second quarter worth about $26,000. Bank of New York Mellon Corp raised its holdings in Lexicon Pharmaceuticals by 43.6% in the first quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 8,335 shares during the last quarter. Finally, R Squared Ltd raised its holdings in Lexicon Pharmaceuticals by 45.0% in the first quarter. R Squared Ltd now owns 67,526 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 20,947 shares during the last quarter. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

The company has a quick ratio of 18.77, a current ratio of 18.80 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.03 billion, a PE ratio of -33.00 and a beta of 0.97. The firm’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.04. The business had revenue of $21.10 million during the quarter, compared to analysts’ expectations of $9.79 million. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. On average, research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.19 earnings per share for the current fiscal year.

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.